Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal. [electronic resource]
Producer: 20210305Description: 484-491 p. digitalISSN:- 1941-837X
- Adult
- Age of Onset
- Cladribine -- adverse effects
- Cost-Benefit Analysis
- Disease Progression
- Female
- Fingolimod Hydrochloride -- adverse effects
- Health Expenditures -- statistics & numerical data
- Health Resources -- economics
- Humans
- Immunosuppressive Agents -- adverse effects
- Male
- Markov Chains
- Middle Aged
- Models, Economic
- Multiple Sclerosis, Relapsing-Remitting -- drug therapy
- Portugal
- Quality-Adjusted Life Years
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.